CAR T-Cell Therapy

With the rapid advancement of CAR T, there is no doubt that many patients in the future will reap the benefits.

Liso-cel was found to improve quality of life in patients with large B-cell lymphoma compared with standard of care.

Cilta-Cel produced an overall response of 95% in patients with heavily pretreated multiple myeloma.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

Tisagenlecleucel failed to improve event-free survival in the second-line setting of relapsed or refractory aggreesve B-cell non-Hodgkin lymphoma versus standard-of-care.

Updated results from CARTITUDE-1 reveal deep and durable response to ciltacabtagene autoleucel treatment in patients with multiple myeloma.

According to findings of the ZUMA-12, axicabtagene ciloleucel can induce durable responses in patients with large B-cell lymphoma.

Compared with standard of care, ciltacabtagene autoleucel produces better responses in the setting of heavily pretreated multiple myeloma.

A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.

To address an unmet medical need for agents to treat B-cell malignancies, the FDA has granted an RMAT designation to CTX110, a chimeric antigen receptor T-cell therapy.

Eleven months after a 43-year-old woman with diffuse large B-cell lymphoma completed chimeric antigen receptor T-cell therapy, she complained of fever, night sweats, and back pain.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.

The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma.

All clinical trials of allogeneic CAR T cells developed by Allogene Therapeutics, Inc have been halted by the FDA pending an investigation of a chromosomal abnormality event.

Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.

Lee Greenberger, PhD, evaluates novel immunotherapies in non-Hodgkin lymphoma for World Lymphoma Awareness Day.

Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.

To address toxicities related to cellular therapy, MD Anderson Cancer Center will now offer the CaspaCIDe safety switch from Bellicum Pharmaceuticals.

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.

The BELINDA clinical trial results show that tisagenlecleucel did not outperform standard of care in aggressive B-cell non-Hodgkin lymphoma.

The off-the-shelf iPSC-derived NK Cell agents, FT516 AND FT596, which are being developed for the treatment of B-cell malignancies, show promise and early clinical benefit.